Related by context. All words. (Click for frequent words.) 65 ascending doses 60 dose titration 60 multicenter randomized placebo controlled 59 dose dose escalation 59 dosage regimens 59 bolus dose 59 placebo controlled 59 placebo controlled clinical 58 dose regimens 58 paroxysmal AF 58 ascending dose 58 nonrandomized 57 dose escalation study 57 randomized multicenter 57 bolus injection 57 Atu# 57 multicenter placebo controlled 57 dosing 56 randomized placebo controlled 56 moderately emetogenic cancer 56 dosing schedules 56 fistulizing Crohn disease 56 oral rivaroxaban 56 DMARD therapy 56 placebo controlled studies 56 platelet inhibitor 56 dosage regimen 56 pharmacodynamic profile 56 placebo controlled randomized 56 pharmacokinetics PK 56 BoNTA 56 dosing cohort 56 dose escalation Phase 55 blind randomized 55 desvenlafaxine succinate 55 rt PA 55 placebo controlled Phase 55 antiarrhythmic drugs 55 dosing regimens 55 continuous intravenous infusion 55 subcutaneous injections 55 blind randomized placebo 55 phase 2a 55 analgesic efficacy 55 administered subcutaneously 55 prospective randomized controlled 55 fluticasone furoate 55 teriflunomide 55 dose cohorts 55 events AEs 55 pharmacodynamics PD 55 ascending dose study 55 active comparator 55 INFERGEN 54 intra articular injections 54 RezularTM 54 titration regimen 54 timepoints 54 interferon beta 1b 54 apremilast 54 double blind placebo 54 randomized multicentre 54 masked placebo controlled 54 KAPIDEX 54 leucine rich 54 randomized #:#:# 54 dose cohort 54 Phase IIIb 54 divalproex sodium 54 de novo kidney transplant 54 dose escalation trial 54 prospectively randomized 54 dosed orally 54 blind randomized controlled 54 HCV RESPOND 2 54 adjunctive placebo 54 mg/m2/day 54 DLTs 54 subcutaneous SC 54 PPAR gamma agonist 54 TNF alpha inhibitor 54 salmeterol fluticasone 54 blind multicenter 54 inhaled fluticasone 53 multicenter randomized 53 IBS C 53 prucalopride 53 docetaxel Taxotere ® 53 ribavirin RBV 53 GnRH antagonist 53 oral prednisone 53 Lamictal XR 53 intravenous dosing 53 gadobutrol 53 Randomised 53 intravenous IV infusion 53 #mg QD [002] 53 dosing regimen 53 VEGF inhibitor 53 blind placebo controlled 53 bupropion SR 53 mcg BID 53 dexamethasone Decadron 53 μg kg 53 injected subcutaneously 53 IV bolus 53 intermittent dosing 53 observer blinded randomized 53 receptor tyrosine kinase inhibitor 53 Placebo controlled 53 atazanavir ritonavir 53 AIR# [001] 53 PEG IFN 53 VA# [002] 53 EVIZON 53 EXPAREL TM 53 #mg/m# [002] 53 direct thrombin inhibitor 53 prospective randomized 53 pharmacokinetic PK study 53 doxorubicin docetaxel 53 double blinded placebo 53 mg kg dose 53 piperacillin tazobactam 53 subcutaneously administered 53 #mg dose [001] 53 DAPT 53 rFVIIa 53 irbesartan 53 PRADAXA #mg 53 ibandronate 53 ADP receptor antagonist 53 blind placebo 53 PEGINTRON TM 53 FOLPI 53 Butrans 53 multicentre 52 nab paclitaxel 52 fluticasone salmeterol 52 dose escalation 52 blinded randomized placebo controlled 52 PICSO ® 52 RSD# oral 52 eptifibatide 52 opioid naive 52 zotarolimus 52 oral levofloxacin 52 Phase 2b study 52 oral prodrug 52 serotonin norepinephrine reuptake inhibitor 52 coadministration 52 phase IIb clinical 52 superficial bladder cancer 52 intravitreal injection 52 bisoprolol 52 q#h 52 ACTEMRA TM 52 Phase 1b 52 mg dose 52 ritonavir boosted 52 daily subcutaneous injections 52 multicenter randomized double 52 ALT flares 52 mycophenolate mofetil MMF 52 REMINYL ® 52 multicentre randomized double 52 corifollitropin alfa 52 paclitaxel poliglumex 52 caspofungin 52 Phase III randomized 52 nucleoside analog 52 cinacalcet 52 placebo controlled clinical trials 52 label dose titration 52 Initiated Phase 52 Dose escalation 52 placebo controlled trials 52 fallopian tube cancers 52 BID dosing 52 multicenter Phase III 52 transient ischemia 52 viral kinetic 52 prospective multicenter 52 Phase 1a 52 sirolimus eluting 52 alpha blocker 52 GOUT 52 immunomodulatory therapy 52 timolol 52 CHOP chemotherapy 52 MIRCERA 52 dose pharmacokinetic 52 8mg/kg 52 mg QD 52 intramuscular injections 52 RLAI 52 dosing intervals 52 intra articular injection 52 beta blocker therapy 52 VIRAMUNE XR 52 Peg IFN 52 suppressive therapy 52 ropinirole 52 venlafaxine ER 52 docetaxel chemotherapy 52 lenalidomide dexamethasone 52 Phase #/#a 52 blind multicentre 51 systemic hypotension 51 phase Ib 51 intravenous dose 51 alpha 2b 51 clotrimazole 51 fosbretabulin 51 CYP#D# inhibitor 51 glycoprotein IIb IIIa inhibitor 51 multicenter 51 acute HAE attacks 51 riociguat 51 hour bronchodilation 51 Q#IR 51 intravenous bolus 51 ENDEAVOR II 51 rotigotine 51 randomized multicenter trial 51 deferiprone 51 #mg dose [003] 51 androgen ablation 51 assessing T DM1 51 Darusentan 51 IIa trials 51 randomized controlled 51 paclitaxel eluting stents 51 cetrorelix pamoate 51 maximally tolerated dose 51 boosted protease inhibitor 51 LEXIVA r 51 corticosteroid therapy 51 ritonavir boosted atazanavir 51 ORENCIA ® 51 Dasatinib 51 ORMD 51 rhIGF-I/rhIGFBP-3 51 tapentadol ER 51 gout flares 51 IIIa inhibitor 51 PULMICORT RESPULES 51 MMP inhibitor 51 antiarrhythmic drug 51 intravenous cyclophosphamide 51 HCV SPRINT 51 label multicenter 51 CK # administered 51 dorzolamide 51 paclitaxel Taxol R 51 prospective multicenter randomized 51 Phase IIa trial 51 trastuzumab Herceptin ® 51 label dose escalation 51 selective phosphodiesterase 51 prednisolone acetate 51 antiepileptic drugs AEDs 51 multicenter prospective 51 carboplatin Taxol 51 dihydroergotamine DHE 51 mg administered orally 51 anticoagulation therapy 51 mycophenolate mofetil 51 QTc 51 refractory NSCLC 51 dose regimen 51 Pharmacokinetics PK 51 subcutaneous enoxaparin 51 Phase 1b trial 51 RSD# 51 titration phase 51 rHuEPO 51 efavirenz EFV 51 #mg BID [001] 51 morphometric vertebral fractures 51 BYSTOLIC 51 TNF inhibitor 51 #mg/m# [001] 51 genotypic resistance 51 MIRAPEX ER 51 AGILECT R 51 treprostinil 51 ABC/3TC 51 tranylcypromine 51 MIRAPEX 51 #.#mg dose 51 randomized 51 sequential dose escalation 51 monoamine oxidase inhibitor 51 ketorolac 51 mg TID 51 pegylated interferon alfa 2a 51 abacavir lamivudine 51 saline placebo 51 randomized double 51 Phase IIa clinical 51 GAMMAGARD 51 citalopram 50 Perforomist Inhalation Solution 50 multidose 50 TMC# r 50 3TC lamivudine Epivir 50 Phase 2a clinical 50 certolizumab 50 aplindore 50 phase IIb trial 50 doxorubicin cyclophosphamide 50 nimodipine 50 latrepirdine 50 mixed amphetamine salts 50 thromboprophylaxis 50 BENICAR 50 tirofiban 50 virological response 50 intramuscularly 50 tacrolimus ointment 50 Prograf ® 50 dose proportional pharmacokinetics 50 Plecanatide 50 generation purine nucleoside 50 oral renin inhibitor 50 hematologic toxicities 50 dosing interval 50 mixed hyperlipidemia 50 multicenter Phase II 50 treatment naive genotype 50 blind randomized multicenter 50 chlorambucil 50 SLx 50 concurrent chemoradiation 50 Insulin PH# 50 flecainide 50 randomized controlled Phase 50 placebo controlled dose escalation 50 LEP ETU 50 factorial design 50 relapsed MM 50 phase IIIb 50 evaluating Xcytrin 50 timepoint 50 peg IFN 50 ADVANCE PD 50 PRECiSE 50 solifenacin 50 multicenter randomized controlled 50 biliary tract cancer 50 aspirin clopidogrel 50 APTIVUS r 50 ruxolitinib 50 factor Xa inhibitor 50 mg BID 50 CIMZIA TM 50 interferon alfa 2b 50 Twinrix 50 #mg/#mg 50 phase IIa 50 nitrofurantoin 50 ritonavir boosted lopinavir 50 clomipramine 50 nicardipine 50 goserelin 50 intravenous doses 50 levetiracetam 50 VersaFilm 50 rilpivirine 50 telaprevir dosing 50 QTcF 50 parathyroid hormone PTH 50 Phase 2b randomized 50 hypomagnesemia 50 TMC# C# 50 thromboembolic complications 50 dyskinesia PD LID 50 MabCampath 50 Traficet EN 50 vapreotide acetate 50 demonstrated antitumor activity 50 chemoradiotherapy 50 oral corticosteroid 50 GEM OS2 50 isoproterenol 50 somatostatin analog 50 inhaled corticosteroid ICS 50 subcutaneous doses 50 intravesical 50 prospective randomized multicenter 50 zaleplon 50 Fingolimod 50 CIMZIA TM certolizumab pegol 50 5-FU/LV 50 ROCKET AF 50 plus dexamethasone 50 zonisamide SR 50 blinded placebo controlled 50 MAS XR 50 safety tolerability pharmacokinetic 50 CorVue ™ 50 dexpramipexole 50 Phase Ib clinical 50 forodesine 50 headache nasopharyngitis 50 eszopiclone 50 Glypromate 50 fluvastatin 50 beta2 agonist 50 Symbicort SMART 50 HCD# [002] 50 multicenter multinational 50 topical steroid 50 OMS# 50 antiretroviral regimen 50 ABSORB trial 50 AZOR 50 migraine prophylaxis 50 Phase 1b clinical 50 mg/m2 cohort 50 ALGRX 50 #mg/day [001] 50 daunorubicin 50 single ascending dose 50 Lixivaptan 50 budesonide formoterol 50 taxane chemotherapy 50 pimecrolimus 50 anti arrhythmic drug 50 verapamil 50 Phase 2b 50 MoxDuo 50 IMPACT DCM 50 multicenter Phase 50 LPV r 50 drug zotarolimus 50 clopidogrel therapy 50 Glatiramer acetate 50 Acute Coronary Syndromes ACS 49 tolterodine ER 49 lomitapide 49 docetaxel Taxotere R 49 Tasimelteon 49 pharmacokinetic profile 49 Ziprasidone 49 Vidaza azacitidine 49 deferoxamine 49 prospective randomized placebo 49 INVEGA SUSTENNA 49 subgroup analyzes 49 Q2W 49 oral anticoagulant therapy 49 dose limiting toxicities 49 randomized crossover 49 elotuzumab 49 guanfacine 49 clevidipine 49 pharmacodynamic effects 49 mesalazine 49 flutamide 49 mg/m2 dose 49 intradermal injections 49 proton pump inhibitor PPI 49 prazosin 49 Ophena 49 galiximab 49 VARIVAX 49 plasma uric acid 49 Intravitreal 49 pegylated liposomal doxorubicin 49 motesanib 49 piroxicam 49 visilizumab 49 PROMACTA 49 Lodotra TM 49 octreotide 49 TEAEs 49 adefovir dipivoxil 49 intravenous infusions 49 Tolvaptan 49 clopidogrel Plavix 49 Lather rinse 49 alefacept 49 GSK# [001] 49 cisplatin vinorelbine 49 EDEMA3 49 dose escalations 49 randomized Phase IIb 49 subcutaneous infusion 49 noninferiority 49 MEVACOR 49 Veramyst 49 corticosteroid dexamethasone 49 pregabalin Lyrica 49 GW# [003] 49 peg interferon 49 darunavir r 49 Phase III placebo controlled 49 oral ribavirin 49 weekly subcutaneous injections 49 CANCIDAS 49 NSTE ACS 49 esomeprazole 49 nulliparous women 49 5FU 49 lanreotide 49 BRIM2 49 azilsartan medoxomil 49 teduglutide 49 histrelin 49 AZILECT R 49 epoetin alpha 49 mitomycin 49 sotalol 49 insulin detemir 49 inhaled tobramycin 49 cannabinor 49 sitaxsentan 49 MVax 49 metastatic HRPC 49 PRE SURGE 49 intravenous bolus injection 49 allergic airway inflammation 49 QD dosing 49 RoACTEMRA 49 oral ibandronate 49 ethambutol 49 TTF Therapy 49 pharmacokinetic profiles 49 synthetic progestin 49 PEGylated interferon beta 1a 49 ZOLINZA 49 phase IIb study 49 CCX# 49 plus ribavirin 49 atherothrombotic events 49 triamcinolone 49 dose escalation phase 49 Ereska 49 phase IIa clinical 49 #mg BID [003] 49 Denufosol 49 ancrod 49 tramadol acetaminophen 49 spontaneous bowel movements 49 efalizumab 49 AIR CF1 49 inhalations twice 49 zolmitriptan 49 Postoperative complications 49 sirolimus eluting stent 49 Microplasmin 49 antiandrogen 49 brivaracetam 49 invasive candidiasis 49 adriamycin 49 including eniluracil ADH 49 corrected QT interval 49 indapamide 49 transaminase elevations 49 dose escalation clinical 49 lamotrigine Lamictal 49 thorough QT 49 rabeprazole 49 amphotericin B 49 pharmacokinetic parameters 49 intratympanic 49 tolerability 49 Crestor rosuvastatin 49 pioglitazone HCl 49 pharmacodynamics 49 milrinone 49 ponatinib 49 APTIVUS 49 multiple ascending dose 49 tolterodine 49 mg qd 49 FASLODEX 49 Phase 2a trial 49 glatiramer acetate 49 subcutaneous formulation 49 abatacept 49 antiplatelet agent 49 Toxicities 49 cold pressor test 49 cerebrovascular events 49 ciclosporin 49 pharmacokinetic characteristics 49 pyridostigmine 49 FIRMAGON 49 inhibitor RG# 49 Platinol 49 epoetin beta 49 recurrent malignant glioma 49 confirmatory Phase III 49 maximal dose 49 multicentre randomized 49 mg RDEA# 49 sirolimus eluting stents 49 VELCADE melphalan 49 Phase III confirmatory 49 mcg doses 49 micafungin 49 Mg Uk 49 NPH insulin 49 intravitreal 49 SCH # 49 Phase 2b clinical 49 dose cyclophosphamide 49 pharmacokinetic studies 49 retinoid 48 virologic failure 48 alpha 2a 48 placebo controlled Phase III 48 bosentan 48 TAXUS IV 48 PEGylated Fab fragment 48 stable angina pectoris 48 INVEGA ® 48 TOVIAZ 48 Phase IIa trials 48 Elitek 48 liver resection 48 intravenous RSD# 48 low dose cytarabine 48 liposomal amphotericin B 48 dinucleotide 48 mesalamine 48 Zileuton 48 idraparinux 48 SomatoKine R 48 Vernakalant 48 Vfend 48 safety tolerability pharmacokinetics 48 epoetin alfa 48 trials RCTs 48 rapid virologic response 48 tamoxifen therapy 48 oral anticoagulation 48 propafenone 48 cytotoxic therapy 48 LYSTEDA 48 CUSTOM III 48 FOLFIRI 48 subcutaneous dosing 48 posaconazole 48 Nasacort AQ 48 mg m² 48 acyclovir Lauriad R 48 glycopyrrolate 48 alkylating agent 48 amoxicillin clavulanate 48 pharmacokinetic PK 48 behind Laura Mentch 48 velafermin 48 Phase IIIb clinical 48 cilostazol 48 multicenter clinical 48 Phase 2b trial 48 darunavir ritonavir 48 JZP 48 gemcitabine Gemzar ® 48 PRT# 48 valsartan amlodipine 48 pharmacologically active isomer 48 titration 48 intradermal injection 48 phase IIb III 48 CONCERTA 48 edoxaban 48 EEG abnormalities 48 calcipotriene 48 Teriflunomide 48 secondary efficacy endpoint 48 adalimumab 48 bosutinib 48 comparator arm 48 catheter occlusion 48 Zenvia ™ 48 pharmacodynamic PD 48 TPI ASM8 48 maximal doses 48 Dapagliflozin 48 Bosutinib 48 diabetic neuropathic pain 48 ATACAND 48 nadroparin 48 ALISTA 48 chronic GVHD 48 PDE4 inhibitor 48 sufentanil 48 antibiotic regimens 48 randomized #:# 48 randomized controlled clinical trials 48 randomized Phase III 48 octreotide acetate 48 Phase 2a 48 Phase 1b clinical trials 48 fluorouracil leucovorin 48 aflibercept VEGF Trap 48 neutropenic sepsis 48 Capesaris 48 randomized clinical trials 48 contraceptive patch 48 mCi 48 unfractionated heparin UFH 48 Pivotal Trial 48 CYPHER R Sirolimus eluting 48 pramipexole 48 dosing cohorts 48 oral alendronate 48 unstable angina UA 48 CLARITY study 48 oral vancomycin 48 ug kg 48 DSMB recommended 48 Laquinimod 48 biologic DMARD 48 mcg QD 48 subcutaneous dose 48 PFO migraine 48 chemotherapeutic regimens 48 icatibant 48 EOquin TM 48 Phase III randomized controlled 48 AZT zidovudine Retrovir 48 antiretroviral regimens 48 phase IIb 48 intranasal steroid 48 events SAEs 48 nonmetastatic prostate cancer 48 subcutaneous methylnaltrexone 48 tenofovir Viread 48 #mg dosing 48 Arikace 48 briakinumab 48 INCB# [003] 48 safety tolerability 48 tinzaparin 48 VEGF receptor inhibitor 48 alemtuzumab Campath 48 NRTI backbone 48 reversible inhibitor 48 abacavir Ziagen 48 refractory CLL 48 epirubicin cyclophosphamide 48 eosinophilic asthma 48 TriRima 48 recurrent GBM 48 RELOVAIR ™ 48 Doxil ® 48 syndrome IBS 48 Dual Opioid 48 mometasone 48 ENMD # 48 Hb levels 48 ZACTIMA 48 opioid induced bowel dysfunction 48 ischemic cardiomyopathy 48 moderate renal impairment 48 beclomethasone dipropionate 48 Randomized controlled 48 protease inhibitor PI 48 lacosamide 48 pharmacokinetics 48 levalbuterol 48 n = 48 bicifadine 48 randomized clinical 48 Decadron 48 PREZISTA ritonavir 48 NSABP B 48 subanalysis 48 alfa 2a 48 4mg/kg 48 basal insulin 48 DEB# 48 formoterol fumarate 48 controlled multicenter 48 nortriptyline 48 Prograf R 48 mesalamine granules 48 small molecule tyrosine 48 rizatriptan 48 ARCOXIA 48 TAXUS stent 48 oral iron chelator 48 GLP1 agonist 48 Aclidinium 48 treatment naïve genotype 48 acitretin 48 pimecrolimus cream 48 HuMax CD4 48 pharmacodynamic profiles 48 bolus dosing 48 virological failure 48 Augment Injectable 48 peginterferon alfa 2b 48 paricalcitol 48 Tarceva TM 48 phase Ib clinical 48 mcg dose 48 melphalan prednisone 48 dopamine partial agonist 48 bronchial thermoplasty 48 double blinded randomized 48 oral diclofenac 48 Androxal TM 48 Phase Ib 48 μg dose 48 perampanel 48 #mg QD [001] 48 efficacy tolerability 48 DDP# 48 unblinding 48 Intrinsa testosterone patch 48 4mg 48 androgen suppression 47 antibiotic prophylaxis 47 immunosuppressive regimen 47 lapatinib Tykerb 47 Phase 1a clinical 47 Flu Cy 47 RRMS patients 47 MAO inhibitors 47 PegIFN RBV 47 dacarbazine 47 Raptiva r 47 Bezielle 47 Randomized placebo controlled 47 cidofovir 47 Cytoxan 47 FIRMAGON R 47 VAPRISOL 47 BRAF inhibitor 47 transdermal gel 47 sublingual formulation 47 partial remissions 47 vecuronium 47 dual antiplatelet therapy 47 DEXILANT 47 orally bioavailable 47 BENICAR HCT 47 intravenous diuretics 47 Targretin capsules 47 dalbavancin 47 Betaferon R 47 REVLIMID lenalidomide 47 tipranavir r 47 TELINTRA 47 systemic corticosteroids 47 lanthanum carbonate 47 heFH 47 CIMZIA R 47 thiazide diuretic 47 cediranib 47 exemestane Aromasin 47 ketoconazole 47 SPIRIT FIRST 47 Ventavis ® 47 mg doses 47 HAART regimen 47 mcg kg 47 prochlorperazine 47 LCP Tacro TM 47 budesonide 47 Safinamide 47 LHRH analogues 47 thalidomide Thalomid 47 oral dosing 47 chemoradiation therapy 47 Ozarelix 47 mecamylamine 47 randomized blinded 47 VNP#M 47 sodium thiosulfate STS 47 non splenectomized 47 chemotherapy docetaxel 47 ARB telmisartan 47 Sym# 47 Allovectin 7 ® 47 otamixaban 47 EDEMA3 trial 47 STRIDE PD 47 GALNS 47 EFFEXOR XR 47 refractory metastatic colorectal cancer 47 β blockers 47 paclitaxel carboplatin 47 intravenously administered 47 everolimus eluting 47 Alzhemed TM 47 gemcitabine carboplatin 47 peginterferon alfa 2a #KD 47 transdermal estradiol 47 tolvaptan 47 Dose Ranging Study 47 paclitaxel Taxol 47 oxcarbazepine 47 NUCYNTA R 47 sorafenib Nexavar 47 ARIKACE 47 dextromethorphan DM 47 mg subcutaneous 47 antiviral efficacy 47 ACAPODENE 47 Primary endpoints 47 orally inhaled migraine 47 risperidone Risperdal 47 HGS# 47 budesonide pMDI 47 recurrent glioma 47 nucleotide analog 47 Tekamlo 47 AZX# 47 alfuzosin 47 null responder HCV 47 recurrent metastatic 47 confirmatory clinical 47 equi analgesic doses 47 prospectively stratified 47 Requip XL 47 Liposomal 47 q8h 47 noninferior 47 OPT CHF 47 Akt inhibitor 47 remifentanil 47 cathepsin K inhibitor 47 Aflibercept 47 MAO inhibitor 47 postprandial glycemia 47 5mg/kg 47 interferon ribavirin 47 GSK# [002] 47 deferasirox 47 Acute Ischemic Stroke 47 IPX# 47 brand ciclesonide HFA 47 mg mL 47 gamma secretase inhibitor 47 #mg ATC 47 SUSTENNA TM 47 mg kg IV 47 nCPAP 47 receiving INTRON 47 lopinavir r 47 budesonide foam 47 leukotriene receptor antagonist 47 desvenlafaxine 47 Torisel 47 NEVO 47 evaluating Vectibix 47 randomized controlled multicenter 47 pegylated liposomal doxorubicin PLD 47 mCRC patients 47 ribavirin USP 47 peginterferon alfa 47 bone marrow reticulin deposition 47 orally dosed 47 blinded randomized 47 Dyloject TM 47 symptomatic BPH 47 II Clinical Trial 47 USL# 47 hemodialysis patients 47 severe hypersensitivity reactions 47 cetuximab Erbitux ® 47 HZT 47 TLK# 47 Phase Ib study 47 metered dose inhaler MDI 47 paliperidone 47 omega interferon 47 Phase IIb clinical trials 47 Multiple Ascending Dose 47 QVA# 47 virologic response 47 demonstrated clinically meaningful 47 serum phosphate levels 47 thienopyridine 47 CIMZIA ™ 47 alvespimycin 47 rilonacept 47 Phase #b/#a trial 47 Amrubicin 47 basal insulin analogue 47 Randomized Phase 47 Phase Ib II 47 GetGoal Phase III 47 therapeutic regimens 47 REYATAZ ritonavir 47 Panzem R NCD 47 montelukast 47 Navelbine ® 47 IV NSCLC 47 colesevelam HCl 47 CR nPR